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Abstract Recent advances in molecular biology, cell
biology and material sciences have opened a new
emerging field of techniques for the treatment of
musculoskeletal disorders. These new treatment
modalities aim for biological repair of the affected
tissues by introducing cell-based tissue replacements,
genetic modifications of resident cells or a combination
thereof. So far, these techniques have been successfully
applied to various tissues such as bone and cartilage.
However, application of these treatment modalities to
cure intervertebral disc degeneration is in its very early
stages and mostly limited to experimental studies in
vitro or in animal studies. We will discuss the potential
and possible shortcomings of current approaches to
biologically cure disc degeneration by gene therapy or
tissue engineering. Despite the increasing number of
studies examining the therapeutic potential of biolog-
ical treatment strategies, a practicable solution to
routinely cure disc degeneration might not be available
in the near future. However, knowledge gained from
these attempts might be applied in a foreseeable future
to cure the low back pain that often accompanies disc
degeneration and therefore be beneficial for the pa-
tient.
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Introduction
The term tissue engineering has been first used in 1989
at a NIH National Science Foundation workshop and
describes the development of a, often cell-based, bio-
logical replacement to restore, maintain, and improve
the function of damaged tissues and organs. Recent
developments in molecular biology, material sciences
and improved knowledge of the human genome con-
tributed that tissue engineering became a proliferating
field of research with widespread clinical applications
[181]. Combination of tissue engineering with gene
therapeutic approaches to modify and tailor the prop-
erties of the used cells even multiplied the power of
tissue engineering. Advanced knowledge about
molecular changes in various diseases and the advances
in tissue engineering laid the base for biological and
specifically aimed approaches to cure musculoskeletal
diseases.
Recently, orthopedic applications of gene therapy/
tissue engineering approaches have been successfully
tested in animals or even in clinical trials (reviewed in
[88]). For example gene therapy for rheumatoid
arthritis [48], orthopedic bone and soft tissue tumors
[158], Duchenne’s/Becker’s muscular dystrophy [168],
haemophilia [73, 98, 128] and osteogenesis imperfecta
[78] have been tested in phase I clinical trials. How-
ever, there are yet no human gene therapy trials in
tissue repair of cartilage-like tissue as articular carti-
lage, meniscus, ligaments and tendons [88]. The same is
true for the intervertebral disc.
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Like no other musculoskeletal tissue, the lumbar
intervertebral disc undergoes very extensive destructive
changes with age and degeneration, respectively [26]
(Fig. 1). The overall degree of this tissue destruction is
closely linked to age but the extent of alterations varied
notably between the different components of the disc
[33]. Substantial individual differences were observed
resulting in young individuals exhibiting the disc of an
elderly person and vice versa [25]. Furthermore, there is
no close link between degeneration and pain. Several
MRI studies have revealed that the rate of asymptom-
atic disc degeneration can range from 7–72% in indi-
viduals who did never experience relevant low back
pain (LBP) [23, 156, 215]. We concur with Vernon-
Roberts [204, 205] that differentiating normal ageing
from pathological degeneration is very difficult. We
therefore use the term ‘‘disc degeneration’’ to indicate
the aforementioned changes without implying that disc
degeneration is synonymous with a painful disc. Nev-
ertheless, many clinicians and researchers believe that
the intervertebral disc is a predominant source of LBP
because of the extensive destructive changes that ulti-
mately lead to an ankylosed motion segment [204, 205].
In this review, we will discuss recent findings
regarding molecular mechanisms that are involved in
causing or propagating degenerative alterations of the
intervertebral disc. We will also relate these findings to
recent developments of biological strategies to therapy
disc degeneration.
Morphological hallmarks of disc degeneration
Intervertebral discs (IVD) provide flexibility to the
spine (bending and rotation) and transmit loads from
body weight and muscle activity. The discs consist of
three highly specialized structures, the endplates, the
anulus fibrosus and the nucleus pulposus.
The two cartilaginous endplates form the inferior
and superior interface between the disc and the adja-
cent vertebrae, therefore enclosing the disc axially. The
anulus fibrosus is made up of several lamellae con-
sisting of parallel collagen fibers interspersed by elastin
fibers [129, 221]. Surrounded by the anulus fibrosus is
the nucleus pulposus, the gelatinous core, which con-
sists of randomly organized collagen fibers, radially
arranged elastin fibers and a highly hydrated aggrecan-
containing gel [82, 222]. The highly hydrated proteo-
glycans in the nucleus pulposus are essential to main-
tain the osmotic pressure and therefore have a major
effect on the load bearing properties of the disc [124].
Anulus fibrosus and nucleus pulposus also differ in the
morphology of their cellular components. The cells of
the anulus fibrosus show a fibroblast-like morphology
in the outer anulus and are rather chondrocyte-like in
the inner region, whereas the cells of the nucleus
pulposus are usually chondrocyte-like with single cells
located in matrix-surrounded lacunae [30, 166, 210].
Besides the outermost part of the anulus fibrosus, the
healthy adult intervertebral disc is accepted to be
avascular [36, 49]. The blood vessels found in the outer
anulus fibrosus seem to originate from the adjacent
longitudinal filament [24].
With increasing age, as growth and skeletal matu-
ration proceed, degenerative processes begin to change
the morphology and therefore the function of the disc.
This is also reflected by changes in the biosynthesis and
denaturation of the extracellular matrix during pro-
gressing age [11, 12]. The nucleus pulposus of degen-
erated discs is characterized by a decreased water and
Fig. 1 Degenerative changes
of the intervertebral disc.
Comparison of young and
healthy (a, c) and severely
degenerated (b, d) discs
illustrates that alterations are
observed in all anatomical
regions of the disc and are
obvious on macroscopical (a,
b) and histological (c, d) level
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proteoglycan content leading to the loss of its gel-like
appearance and hydrostatic properties [26, 124].
Degenerative changes of the anulus fibrosus are less
obvious, but result in irregular lamellae with the col-
lagen and elastin networks becoming more disorga-
nized.
Replacing the gel-like structure of the nucleus
pulposus with fibro-cartilaginous tissue results in de-
creased flexibility and therefore often in cleft forma-
tion with fissures. Cell proliferation is often observed in
the nucleus leading to formation of lacunae containing
multi-cell clusters [68, 85]. Despite the observed signs
of cell proliferation, up to 50% of the cells show signs
of necrosis and some of them reveal signs of apoptosis,
potentially resulting in a cell loss from the disc [62, 159,
199].
Although there is broad consensus about these
hallmarks of degeneration, the question if neo-vascu-
larization and/or neo-innervation of the inner parts of
the disc occur during degeneration is still discussed [51,
86, 115]. Several studies describe neo-vascularization
of the inner portions of the disc, possibly accompanied
by nerve fibers, however, it is not completely clear at
which stage of degeneration neo-vascularization occurs
[29, 43, 67, 86, 150, 151, 161, 188]. Clarification of this
question is of special importance since the interplay
between neo-vascularization and neo-innervation
might be of crucial importance for the pain sensation
caused by degenerated discs.
Etiology of disc degeneration
Although the etiology of disc degeneration is far from
being understood, there is consensus that not a single
factor can be hold responsible for the complex phe-
nomenon of disc degeneration. Rather a multitude of
exogenous and endogenous factors, each contributing
individually, might influence the progress of degener-
ative changes of the discs. These factors can be divided
into three main groups: mechanical load, genetic pre-
disposition, and nutritional effects.
Effects of mechanical load
Originally, injuries due to abnormal loads were
thought to be the main cause for structural alterations
that initiate the process of degeneration and finally
lead to back pain [7]. Since then a multitude of studies,
involving humans and experimental animals have been
undertaken to investigate the correlation between
mechanical load and disc degeneration.Although it is
not clearly shown that the disc itself is directly suffering
from abnormal loads [174], it seems possible that
mechanical injury of adjacent vertebral bodies con-
tributes to the initiation of disc degeneration [3].
However, several studies attempting to link disc
degeneration to mechanical factors, such as heavy
physical work, lifting, etc., failed to provide direct
evidence for a causal relationship between back pain
and mechanical load-induced disc degeneration [41,
70]. There is the possibility that these results are ob-
structed by additional factors like occupation, psycho-
social factors and environment that might be involved
in the patient’s perception of discogenic back pain [46,
47]. To investigate the influence of mechanical stress
on disc degeneration and exclude any additional fac-
tors, animal experiments have been carried out.
Application of dynamic, compressive load forces to the
IVD of various animals resulted in changes indicating
the onset of degeneration when the discs were ana-
lyzed morphologically or histologically [31, 80, 106,
121, 122]. Besides the effects of compressive forces also
animals subjected to vibrational forces revealed signs
of degenerative changes [217]. However, even in well-
controlled animal experiments the results were con-
tradictory. At least two studies reported that animals
subjected to long-term compressive load or long-term
intense exercise did not exhibit adverse effects on the
respective IVD [79, 157].
Taken together, the results from clinical studies and
animal experiments are not completely conclusive. The
majority of the animal studies might suggest that cer-
tain forms of mechanical loads suffice to induce disc
degeneration. However, several studies in humans did
not provide a strong causal link between occupational
exposures and disc degeneration, suggesting a more
complex etiology of disc degeneration [206].
Genetic predisposition
Besides the investigations on mechanical influences on
disc degeneration, several studies have demonstrated a
strong familial predisposition for disc degeneration [22,
69, 120, 134, 178, 203, 206]. These findings were con-
firmed by twin studies that revealed an overall herita-
bility between 52 and 74% for disc disease at the
lumbar spine [17, 125, 173], with the genetic effects
becoming more evident as the individuals grow older
[71].
Recent technological advances to analyze the hu-
man genome confirmed the importance of genetic
predisposition by identifying polymorphisms corre-
lated with the occurrence of disc degeneration. The
majority of polymorphisms identified so far affect
genes encoding for proteins of the extracellular matrix.
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A polymorphism located in the gene encoding for
aggrecan correlated with the presence of disc degen-
eration and led to a higher risk for multilevel degen-
eration at an early age [42, 96]Polymorphisms affecting
collagens have mostly been found in collagen type I, II
and IX genes [83, 93, 94, 144, 155, 185]. The mutations
in the collagen type IX genes resulted in the replace-
ment of an original amino acid with tryptophan,
probably affecting integrity and stability of the matrix
interactions [6]. Among the non-collagenous matrix
proteins, polymorphisms in the gene encoding the
cartilage intermediate layer protein (CILP) have been
recently associated with susceptibility to lumbar disc
disease [179]. The authors suggest that CILP is in-
volved in the regulation of TGF-b signaling and that
this regulation might have a crucial role in the etiology
and pathogenesis of disc degeneration [179].
But not only polymorphisms in genes encoding for
matrix proteins have been associated with disc degen-
eration. Recently, mutations in the gene encoding for
the pro-inflammatory cytokine interleukin-1 (IL-1)
have been associated with an increased risk of disc
bulges and degenerative changes in the disc [183, 184].
However, a recent study involving a collective of pa-
tients suffering from intervertebral disc disease-related
sciatica, found genetic variations in IL6, encoding for
IL-6, to play a role in discogenic pain, whereas no
association was found for genetic variations in IL1
[145]. The reason for the discrepancies between these
two studies is not yet clear.
Besides genes encoding for matrix proteins and
signaling factors genetic variations have also been
identified in matrix degrading enzymes. Polymor-
phisms in the promoter responsible for the expression
of the matrix-degrading enzyme matrix metallopro-
teinase-3 (MMP-3) were found to accelerate degener-
ative changes in the lumbar discs in the elderly [193]. In
addition, polymorphisms were found in the gene
encoding the vitamin D receptor [87, 95, 207, 208].
However, the mechanism by which vitamin D receptor
is influencing disc degeneration is unknown.
Most polymorphisms discussed herein affect genes
that are involved in the integrity or functionality of the
disc matrix. This is obvious for the genes encoding
aggrecan or collagen. MMP-3 is a matrix degrading
enzyme and therefore mutations are disturbing the
balance in matrix proteins synthesis and degradation.
IL-1 was found to be involved in the up-regulation of
inflammatory reactions and also MMP-1 and MMP-3
expression, which would finally lead to degradation of
the disc matrix [84]. CILP, on the other hand inhibits
TGF-b-dependent signaling, a growth factor that has
been shown to be important for maintenance of the
disc matrix [15, 152]. These findings suggest that the
genetic background is responsible for the integrity of a
healthy disc. If mutations in these genes occur, nor-
mally innocuous conditions or forces might lead to
accelerated or enhanced degenerative changes, sug-
gesting that disc degeneration may be explained pri-
marily by genetic influences and that environmental
factors have only modest effects [17]. However, it is
important to keep in mind that despite the dominating
role of genetic predisposition, Adams et al. stressed
that injuries can occur when normal forces are applied
to abnormally weak tissues, or when abnormally high
forces are applied to normal tissues [2].
Nutritional effects
Insufficient nutritional supply of the disc cells is
thought to be a major problem contributing to disc
degeneration. Since the intervertebral disc is the larg-
est avascular tissue in the human body, its cells are
facing the precarious situation of having to maintain a
huge extracellular matrix with a ‘‘fragile’’ supply of
nutrients that is easily disturbed (Fig. 2). Whereas the
cells in the outer anulus fibrosus may be supplied with
nutrients from blood vessels in the adjacent longitudi-
nal ligaments, the supply of the nucleus pulposus cells
is almost completely dependent on the capillary net-
work in the vertebral bodies [37, 49, 131, 202]. Due to
the size of the intervertebral disc, the nutrients need to
diffuse from the capillaries through the endplate and
the disc matrix to the cells in the nucleus of the disc.
With the originally cartilaginous endplates becoming
calcified when degeneration progresses, the supply
with nutrients will become even more restricted [167].
Not only the supply with nutrients like glucose and
oxygen is restricted due to diffusion distances, also the
removal of metabolic waste, i.e. lactic acid, becomes
critical [75]. Measurements demonstrated that oxygen
concentrations were very low in the nucleus and in-
creased towards the disc surface, the lactic acid con-
centration showed the reverse profile. Since lactic acid
is not only the major waste of disc cells but also an
acid,its accumulation results in a lowered pH inside the
disc [16]. In vitro experiments have shown that low
oxygen concentrations and acidic pH significantly af-
fect the synthetic activity and especially proteoglycan
synthesis rates of disc cells, which might lead to a fall in
proteoglycan content and therefore to disc degenera-
tion in vivo [147].
Taken together, these adverse conditions may lead
to increased cell death and therefore reduced cell
numbers in the disc [21, 76]. As a consequence, the
very few remaining cells are confronted with the task
450 Eur Spine J (2007) 16:447–468
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to maintain an extensive matrix. It is conceivable that
the progress of matrix degeneration becomes irre-
versible once the cell density falls below a minimal
threshold. This would directly link the restriction of
nutrients with the final destruction of the discal matrix.
Molecular mechanisms of degeneration
Induction of the degeneration process requires the
translation of the adverse impacts discussed above, i.e.
nutritional restrictions and mechanical stress into
molecular mechanisms. It is thought that the disc cells
serve as integrators that translate the various impacts
into molecular mechanisms, such as expression of an
array of matrix degrading enzymes, changes of the disc
cell phenotype or initiation of signal transduction cas-
cades. In this review, we will focus on gene products
that are suspected to be involved in disc degeneration
or whose expression levels have been found to change
dependent on the degeneration grade of the disc and
are therefore of special interest for the design of bio-
logical treatment strategies.
Matrix degrading enzymes
Disorganization of the disc matrix is one of the pre-
valent features of disc degeneration. According to the
major constituents of the matrix, collagens, proteogly-
cans and fibronectin, several classes of enzymes are
produced by disc cells that specifically break down these
components (summarized in Table 1). The most domi-
nant and best-characterized group of degrading en-
zymes is the matrix metalloproteinases (MMPs). MMPs
are responsible for degradation of the various types of
collagens found in many tissues and are classified
according to their specificity [60]. Activation of MMPs
during degenerative disc disease might be of ambiguous
benefit. Whereas MMP activation in intact discs might
contribute to the degeneration of matrix molecules and
therefore be unfavorable, it might be beneficial in her-
niation by supporting the resorption of the prolapsed/
extruded tissue. Herein, we will focus on MMPs in-
volved in degeneration and therefore mainly discuss
MMP expression in degenerated but contained discs.
The presence of MMPs in correlation with interver-
tebral disc degeneration has been investigated in vari-
ous studies using cadaveric and surgical disc specimens
[34, 90, 111, 165, 214]. All these studies indicated that
MMPs are produced by disc cells in increasing amounts
with increasing degeneration of the disc matrix. MMPs
from all three matrix degrading classes (MMP-1, -2, -3, -
9) displayed a very similar expression pattern and were
also found to correlate with the occurrence of clefts and
tears in the intervertebral disc matrix.
In additional studies, the use of herniated disc
material from non-contained discs might result in false
high results due to influences of extra-discal inflam-
matory cells infiltrating the herniated material and
inducing MMP expression [44]. The knowledge gained
from studies applying human specimens were further-
more confirmed by animal experiments. Anderson
et al. showed that in a rabbit laceration model, mac-
roscopic injury to the disc led to a significant increase
in the expression of MMP-1, -9, -13 [10].
These in vivo studies have been supplemented by in
vitro experiments to study aspects of the regulation of
MMP expression in disc cells. It has been shown that
disc cells isolated from degenerated discs of various
animals and also from humans synthesize MMPs in
vitro either spontaneously [91, 92, 139], under hydro-
static pressure [66] or after stimulation by interleukin-1
[84, 112, 180].
Besides regulation of its expression, MMP activity is
regulated at two additional levels: on the post-trans-
lational level by proteolytic activation of the zymogen
Nutrient supply
Waste removal
lac pO2, glc
Fig. 2 Limitations of the nutrient supply to cells of the nucleus
pulposus. Due to the avascularity of the intervertebral disc
nutrient supply and waste removal is entirely relying on diffusion
through the cartilaginous endplates. This results in a gradient
through the disc with a minimum of nutrients (pO2, glc glucose)
and a maximum of waste products (lac lactate) in the middle of
the disc
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and the activated enzyme is furthermore modulated by
its binding to tissue inhibitors of matrix metallopro-
teinases (TIMPs) determining the amount of free, ac-
tive proteinases [189]. So far, three TIMPs have been
detected in various tissues; TIMP-1, -2, and –3.
Expression of TIMP-1 and -2 was found to increase in
degenerated discs, whereas TIMP-3 expression did not
significantly increase with increasing degeneration
[111, 143]. These findings might suggest that the in-
creased expression of MMPs may be counteracted by
the increased TIMP levels [111]. However, Kanemoto
et al. could not detect TIMP-1 in most of the analyzed
surgical specimens that were also positive for MMP-3,
suggesting an imbalance between MMP-3 and TIMP-1
as a cause for disc degeneration [90].
Besides collagens, aggrecan, a large proteoglycan, is
also degraded during degeneration. Although MMP-
generated and aggrecanase-generated fragments of
aggrecan have been localized in IVD, role and identity
of the respective aggrecanases during degeneration has
yet to be clarified [165, 191]. One candidate is the so-
called aggrecanase-1 or ADAMTS4 (a disintegrin and
metalloproteinase with thrombospondin motifs 4) that
has been found to increase with increasing degenera-
tion [111]. Interestingly, the increase in ADAMTS4
expression was not paralleled by a rise of its inhibitor
TIMP-3, suggesting that ADAMTS4 might play an
important role in tissue degradation during disc
degeneration [111].
Besides the well-characterized MMPs, cathepsins
are another group of dominant proteinases able to
degrade collagen and proteoglycans. Although cath-
epsins potentially contribute to degradation of the disc
matrix, only few studies investigated a role of cathep-
sins in degenerative disc disease. Immunohistochemi-
cal analysis of cathepsins demonstrated that cathepsins
D, L, K and G were found in increasing amounts in
degenerated disc tissue and were associated with end-
plate separation and disorganization of the anulus fi-
brosus during degenerative disc disease [13, 103].
Although the exact mechanisms of cathepsin up-regu-
lation are unknown, pro-inflammatory cytokines and
growth factors have been reported to be involved in
regulation of cathepsins [40, 45, 57, 58, 200, 211].
Since the substrate range of cathepsins and MMPs
significantly overlap, the distinctive role of the two
classes of proteinases during disc degeneration is not
completely clear. However, it has been shown, that
MMPs prefer neutral pH, whereas cathepsins show
maximal activity in an acidic environment [138]. This
preference of cathepsins for acidic pH might suggest a
role for this class of matrix degrading enzymes later
during degeneration when accumulation of lactic acid
already led to a lowered pH in the discal matrix.
Pro-inflammatory mediators
Disc cells do not only produce matrix-degrading en-
zymes but also have the ability to initiate or propagate
signal transduction cascades to manipulate their own
environment. Production and secretion of cytokines,
growth factors and the respective receptors by disc
cells has been investigated extensively (summarized in
Tables 2, 3). However, the knowledge gained so far
originates from very heterogeneous experimental set-
ups including studies on herniated discs (protruded,
extruded or sequestrated discs), in vitro experiments or
the use of animal models. Therefore it is often very
difficult to undoubtedly identify the origin of cytokines
and growth factors found in disc tissue.
However, analyses of disc tissue and isolated disc
cells revealed that disc cells do have the ability to
Table 1 Matrix degrading
enzymes playing a role in
intervertebral disc
degeneration and its
inhibitors (references given
refer to studies discussing the
role of the respective enzyme/
inhibitor in disc
degeneration)
MMP matrix
metalloproteinase, ADAMTS
a disintegrin and
metalloproteinase with
thrombospondin motifs,
TIMP tissue-specific inhibitor
for metalloproteinases
Enzyme Synonym Substrate References
Degrading enzymes
MMP-1 Collagenase I Collagen I, II, III, VII, X [10, 44, 165, 201, 214]
MMP-2 Gelatinase A Gelatin I [165, 214]
MMP-3 Stromelysin 1 Gelatin I, III, IV Collagen III, IV,
X Fibronectin Proteoglycans
[139, 165, 214]
MMP-9 Gelatinase B Gelatin I, V Collagen IV, V [10, 165, 214]
MMP-13 Collagenase III Collagen I [10]
ADAMTS4 Aggrecanase-1 Aggrecan [111]
Cathepsin D Collagen I, II Aggrecan, Link protein [13]
Cathepsin G Collagens [103]
Cathepsin K Collagenolytic activity [13]
Cathepsin L Collagen I, II, IX, XI Aggrecan
Link protein
[13]
Inhibitors
TIMP-1 MMP-inhibitor [111, 143]
TIMP-2 MMP-inhibitor [111]
TIMP-3 Aggrecanase-inhibitor [111]
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produce a wide array of signaling molecules potentially
involved in pro-inflammatory and related pathways.
Among these mediators are the (pro-inflammatory)
signaling molecules IL-1a, IL-1b, IL-6, TNF-a GM-
CSF (granulocyte-macrophage colony stimulating fac-
tor), IL-8, RANTES (regulated on activation, normal
T-cell expressed and secreted), and IL-10 [4, 91, 102,
116, 135, 187, 192, 213]. In addition, inflammatory
mediators such as leukotriene B4, thromboxane B2
and prostaglandin E2 and the respective enzymes in-
volved in the same signaling pathway (phospholipase
A2 and COX-2) were found in contained and non-
contained herniations [91, 102, 135, 146, 169, 192].
Although these results summarize the abilities of disc
cells to synthesize signaling mediators, the respective
set of factors expressed in a certain condition are often
contradictory and will need further investigations.
Despite the observed contradictions, one can assume
that disc cells do have the potential to produce the
inflammatory cytokines necessary to mediate and
propagate an inflammatory reaction. In addition, the
expression of cytokine receptors suggests that these
cells are not only able to initiate signal transduction
cascades but also endue the requirements to react to
pro-inflammatory mediators [187]. Several studies
provide strong evidence, that the chondrocyte-like cells
of the nucleus pulposus are the origin of the observed
mediators in contained, degenerated discs. However,
studies that are more detailed are needed to analyze
the contribution of resident cells and potentially infil-
trating immune cells to the observed levels of pro-
inflammatory cytokines.
Only few studies focused on a possible effect of
cytokine production on the induction of discogenic
pain are therefore of special interest for treatment
strategies of discogenic pain. Burke et al. [28] found
significantly higher levels of IL-6 and IL-8 in discs from
low back-pain patients compared to discs from sciatica
patients, independently on the presence of an intact
anulus fibrosus or nuclear extrusions. Surprisingly, the
levels of prostaglandin E2 were not significantly dif-
ferent between sciatica and LBP patients. The same
authors also demonstrated that nucleus pulposus cells
from degenerate discs were more sensitive to pro-
inflammatory stimuli in vitro compared to cells from
scoliotic control discs [27]. From these studies one can
conclude that cytokines may not only be involved in
the degeneration of the human intervertebral disc but
seem to also play a major role in the pain induction in
the degeneration associated low back-pain symptom.
Growth factors
Growth factors are usually low molecular weight pro-
teins that have the potential to increase mitogenesis,
cytodifferentiation and also matrix synthesis. This
combination of proliferative and biosynthetic effects
on target cells and tissues originally motivated a closer
Table 2 Pro-inflammatory mediators expressed in degenerating intervertebral discs (references given refer to studies discussing the
role of the respective mediator in disc degeneration)
Mediator Function References
IL-1a Pro-inflammatory cytokine MMP-induction [4, 192]
IL-1b Pro-inflammatory cytokine MMP-induction [84, 135, 192]
IL-6 Pro-inflammatory cytokine anti-apoptotic [28, 84, 91, 116, 187, 192]
IL-8 Pro-inflammatory cytokine chemokine [4, 28, 116]
IL-10 Inhibition of pro-inflammatory cytokines downregulation of MMPs [4]
TNF-a Pro-inflammatory cytokine pro-apoptotic [4, 135, 192, 213]
GM-CSF Pro-inflammatory cytokine [192]
RANTES Chemokine [4]
PGE2 Tissue degradation Inflammation angiogenesis [27, 91, 192]
PLA2 Biosynthesis of prostaglandins [169]
COX2 Biosynthesis of prostaglandins [84, 135]
IL interleukin, TNF tumor necrosis factor, GM-CSF granulocyte macrophage-colony stimulating factor, RANTES regulated on
activation, normal T-cell expressed and secreted, PGE2 prostaglandin E2, PLA2 phospholipase A2 COX2 cyclooxygenase-2
Table 3 Growth factors expressed in degenerating
intervertebral discs (references given refer to studies discussing
the role of the respective growth factor in disc degeneration)
Growth
factor
Function (induction of) References
TGF-b Cellular proliferationProteoglycan
synthesis
[104, 187, 196, 198]
IGF-1 Proteoglycan synthesis
(minor effect)
[148, 149, 187]
bFGF Proteoglycan synthesis
(minor effect)
[196, 197]
NGF Formation of nerve fibres [52, 59]
TGF-b transforming growth factor-b, IGF-1 insulin-like growth
factor-1, BFGF basic fibroblast growth factor, NGF nerve growth
factor
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investigation of growth factors and their effects on
cartilage (recently reviewed in [38, 72] and summarized
in Table 3).
The best-characterized growth factors are the
members of the TGF-b family. Application of TGF-b
on disc cells resulted in an anabolic response, charac-
terized by increased proteoglycan synthesis and re-
duced tissue resorption by decreased MMP-2 secretion
[61, 152]. In addition a transient proliferative effect has
been observed on cultivated disc cells [61].
Human disc cells do not only respond to exogenous
TGF-b but are also able to produce this growth factor.
However, the available data are contradictory. Some
studies report TGF-b and its cognate receptor, TGF-b
receptor type II, to be generally found in tissue speci-
mens from human herniated discs, mainly associated
with disc cells or capillaries [187, 198]. Whereas others
demonstrated that TGF-b expression was found only in
a minority of the herniated disc tissue samples and
TGF-b receptor type II could not be detected in any of
the herniated discs [104]. In degenerated, non-herni-
ated IVD there is consensus that TGF-b1 and TGF-b2
are expressed in all examined tissue samples with TGF-
b1-positive cells preferentially located near tissue clefts
[140, 196].
Besides the major growth factor TGF-b, Insulin-like
growth factor-1 (IGF-1) has also been studied in detail.
Similarly to TGF-b, IGF-1 has also been described to
increase proteoglycan synthesis to reduce tissue
resorption in discs by lowering the level of active
MMP-2 [152, 195]. In human herniated discs the in-
creased expression of IGF-1 has been interpreted as an
attempt to repair the extruded disc material [187].
Besides these TGF-b-like functions, IGF-1 also seems
to contribute to the viability of disc cells by its anti-
apoptotic effect [65].
Expression of IGF-1 was found to be produced by
disc cells from many species including humans [148,
149, 187]. Interestingly, animal experiments demon-
strated that IGF-1 production decreased with increas-
ing age suggesting a possible role of IGF-1 in the loss of
proteoglycan synthesis observed with ageing [148, 149].
Besides these two well-investigated growth factors,
less is known about other growth factors in the disc.
Basic fibroblast growth factor (bFGF) is usually pro-
duced by tissues with high angiogenic activity, but is
also found in the majority of samples from herniated
discs and in all examined degenerated disc samples
[196, 197]. The presence of bFGF in small blood vessels
in herniated disc material raises the possibility of
angiogenesis as an additional response by the disc cells
to disc injury.
Recently, an atypical growth factor has been found
inside the human IVD. Nerve growth factor (NGF)
differs from the growth factors discussed so far by not
exhibiting any known proliferative or anabolic func-
tions on disc cells but has been shown to exert neuro-
trophic properties. Therefore, NGF might not be
important for repair or maintenance of the interver-
tebral disc, but might play an important role in pain
induction. This hypothesis was supported by NGF
being exclusively present in pain level discs; whereas
non-pain level discs or normal discs were entirely
negative. NGF-positive cells were either found in
microvascular blood vessels accompanying ingrowing
nerve fibers or in chondrocyte-like cells of anulus fi-
brosus [52, 59]. These findings raise the possibility that
not only neo-vascularization might take place in
degenerated discs but also neo-innervation. Since these
new nerve fibers are only found in pain-level discs
strongly indicates them to be involved in, if not even
responsible for, the difference between degenerated
pain-level and non-pain-level discs.
Therefore, growth factor-targeted interventions to
treat disc diseases would need to either supply the disc
with the lacking anabolic growth factor (such as TGF-
b, IGF-1, etc.) or would target the resulting pain by
inhibiting the actions of NGF.
Biological treatment strategies
Biological therapies to treat degenerated IVD have
mainly been used to support interbody fusions after
discectomy, resulting in a loss of function for the af-
fected motion segment (recently summarized in
[123]), but scarcely to regenerate or cure the degen-
erated, painful disc itself and therefore restore bio-
logical function. This discrepancy is primarily caused
by the unique properties of the intervertebral disc and
the severe alterations that the disc is undergoing
during degeneration that significantly limit the range
of suitable approaches. In addition, the limited
knowledge and often contradictory findings regarding
disc cell biology as discussed above further complicate
biological approaches. In the following, we will dis-
cuss the various techniques that have been developed
and tested to overcome these difficulties and to bio-
logically treat degenerative IVD. Common to these
techniques is the aim for sustained delivery of bio-
logically active factors to the disc that should drive
regeneration or conserve the status quo of the af-
fected tissue. The nature of the respective active
factor is hereby defined by our knowledge of the
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molecular mechanisms active in the disc during the
various stages of degeneration.
So far, four general approaches have been applied:
• Delivery of the ‘naked’ factor by intradiscal injec-
tion (Fig. 3)
• Gene therapy approaches that modify gene expres-
sion of resident disc cells in vivo (direct gene
therapy) (Fig. 4)
• Autologous implantation of cells that have been
antecedently removed, cultivated and often modi-
fied in vitro (Fig. 5)
• Implantation of mesenchymal stem cells (Fig. 6).
The applicability of the various approaches is largely
depending on our current knowledge of disc cell biol-
ogy, the state of degeneration of the intervertebral disc
and also safety concerns.
Direct injection of an active substance
The most straightforward technique to deliver an ac-
tive substance to the disc cells would be its direct
injection into the disc (Fig. 3). Although direct appli-
cation of beneficial factors, mostly proteins like growth
factors, cytokines or anabolic enzymes, has been used
frequently in vitro, only few studies have been pub-
lished attempting this approach in vivo. Promising re-
sults have been reported after injecting rabbit lumbar
IVD in vivo with osteogenic protein-1 (OP-1), a growth
factor belonging to the TGF-b superfamily of growth
factors. Direct injection of this growth factor resulted
in significantly increased proteoglycan synthesis and
also restoration of disc height that was found to be
stable up to eight weeks after injection [9, 194].
Additional studies demonstrated that OP-1 injection
even inhibited pain-related behavior in a rat disc
degeneration model [8, 97]. Although these studies
demonstrate the feasibility of direct injection, this
technique might be limited to the presence of disc cells
that are still healthy, numerous and able to respond
appropriately and to a short term stimulus. In the used
rodent model systems this situation is much more
probably to be encountered compared to other animal
models (and humans) that do differ in the composition
of the disc cell population and weight bearing proper-
ties. Considering the decreasing viability and synthetic
activity of human disc cells during progressing degen-
eration, direct injection approaches are most probably
limited to only mildly degenerated discs. Since mildly
degenerated discs will be primarily found in younger
individuals, an only transient regeneration of the disc
might not countervail the, even though minimally
invasive, intervention. In this context, the rather short
follow-up time common to the current studies (up to
8 weeks) is further limiting conclusions regarding the
applicability of this technique to humans. Further
studies will need to include animal models with IVD
more comparable to the human situation, especially
regarding cell population, cell density and mechanical
loading.
A different approach has been chosen in a clinical
pilot study recently published by Klein et al. [101].
Instead of injecting a biologically active enzyme or
growth factor, the authors injected a mixture of matrix
components and aiding components, the so-called ‘disc
solution’, directly into the disc. After treatment and an
average duration of follow-up of 13 months the pa-
tients responded well regarding reduction in a disabil-
ity score and a visual analogue pain score. The authors
suggested that the good outcome might be due to the
combination of several components resulting in a par-
allel replenishing of the matrix by increased proteo-
glycan synthesis and induction of disc repair by
simultaneous induction of multiple growth factors.
Although controlled comparative studies with in-
creased follow-ups will be needed to further validate
this treatment, this approach might prove superior to
the injection of a single bioactive factor. It is conceiv-
able that the injected matrix components are able to
modulate and improve the intradiscal environment
injection into
degenerated disc
active substance
(growth factor, 
enzyme, etc.)
active substance
embedded in 
slow-release matrix
Fig. 3 Direct injection of an active substance into the interver-
tebral disc matrix. Active substances, such as growth factors or
anabolic enzymes can be injected directly into the disc matrix or
can be injected embedded in a matrix that allows slow release of
the substance into the environment
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enabling the disc cells, even in a severely degenerated
disc, to react to the resulting secretion of growth fac-
tors and continue with the maintenance of the matrix.
However, from this pilot study it is not clear if the
injected components will be contained inside the disc
in heavily degenerated discs and therefore be able to
ensure a prolonged beneficial effect on the disc cells.
Common to these ‘injection techniques’ is the usu-
ally short-term effect that might cease when the orig-
inally injected material has been consumed or is lost to
the disc cells by diffusion. In order to provide the disc
with a continuing supply of beneficial factors, it would
be desirable to continuously produce the factor of
choice or include the substances in a pharmacological
slow-release system as suggested for the use of growth
factors [133]. Considering these data, it is conceivable
that a combination of growth factor injection and ma-
trix replenishment by a ‘disc solution’ might be the way
viral vector
encoding protein X
injection into
degenerated disc
expression of protein X
by transformed disc cells
Fig. 4 Direct gene therapy. Resident cells are genetically
modified in situ in order to express beneficial genes. Modification
is achieved using a carrier (for example gene engineered viral
vectors). After transformation, the resident disc cells show
sustained expression of the beneficial protein (protein X)
harvesting of
disc cells
genetic modification
cultivated cells transformed cells
cell-seeded
scaffold
seeding of
scaffold
implantation of
autologous cells
Fig. 5 Augmentation of
degenerated intervertebral
discs by implantation of
autologous cells. Cultivated
cells could be implanted
directly, genetically modified
in vitro prior to implantation
(indirect gene therapy), or
seeded into a scaffold (tissue
engineering)
harvesting of
bone MSCs
injection of 
differentiated cells
progenitor cells differentiated cells
induction of 
differentiation
injection of 
MSCs
Fig. 6 Augmentation of
degenerated intervertebral
discs by implantation of bone-
derived mesenchymal stem
cells (MSC). Harvested MSC
can be cultivated as
progenitor cells and injected
directly into the disc matrix.
Alternatively, the progenitor
cells can be differentiated in
vitro to a disc cell-like
phenotype and then injected
into the disc matrix
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to obtain a more sustained improvement of degener-
ated discs and might also expand the limitation
regarding its application to various degeneration
grades.
Gene therapy approaches
Prolonged supply of the discal matrix with a beneficial
agent could be achieved by genetically modifying disc
cells in order to produce a desired gene product. Due
to advances in molecular genetics, techniques are
readily available to insert genetic elements (DNA) into
almost any type of target cell. These genetic elements
usually consist of the gene encoding the desired prod-
uct and a control element modulating the expression of
the respective gene. Typically, two strategies can be
used to achieve expression of the desired gene at the
targeted site. In vivo, or direct gene therapy requires
the direct introduction of the gene of interest into
resident cells in situ (Fig. 4), whereas indirect, or ex
vivo gene therapy requires the removal of target cells,
introduction of the gene of interest in vitro and
implantation of the transformed cells (Fig. 5) [141].
Since the uptake of pure, ‘naked’ DNA into host cells
is usually not very efficient [216], uptake of the desired
genetic material can be improved by application of a
carrier, also called vector.
Two classes of vectors are currently used: non-viral
vectors and viral vectors. Non-viral transporters are
either molecular complexes of the DNA and a ligand
[118], liposomes containing DNA [126], or particle-
mediated gene transfer (‘gene gun’) [218]. Generally,
the disadvantages of non-viral transporters are the ra-
ther poor expression of the transferred DNA and the
limited efficiency, resulting in a restricted number of
transformed cells. In addition, the introduced gene
usually remains episomal, i.e. it will not be integrated
into the genome of the target cell, and is therefore
prone to be lost from the cell. Although, these non-
viral systems have been rarely used in approaches to
the treatment of degenerative disc disease, recent
developments have improved the efficiency and in the
future non-viral vectors might become interesting for
treating disc disorders [117].
Viral vectors are very efficient transporters of ge-
netic material; they are able to enter mammalian cells,
taking over DNA replication and the protein expres-
sion machinery. For the purposes of gene therapy,
several engineered viruses are available that have the
original viral genome removed or inactivated and in
addition are modified to not replicate nor exhibit their
pathogenicity. Properties of currently used viral vec-
tors have been recently described by Gardlik et al. [56].
In summary, these viruses vary in their ability to inte-
grate the transferred DNA into the host cell genome,
their ability to invade dividing or non-dividing cells and
their infection efficiency. Due to the properties of the
intervertebral disc and its cells, the virus of choice
needs to efficiently infect non-dividing, quiescent cells.
In addition, the low cell density inside the disc might
hamper efficient infection of a sufficient fraction of the
disc cells. On the other hand, the encapsulated and
avascular tissue would provide an advantageous envi-
ronment to achieve high concentrations of the injected
viral vector, leading to higher efficiency of the infection
process and also lessens the danger of an immune re-
sponse against viral proteins.
During 1997, the first successful virus-mediated
transfers of potentially therapeutic genes into disc cells
have been published [160, 212]. Isolated disc cells from
bovine or rat discs were successfully transformed by a
retroviral construct containing the gene for the human
interleukin-1 receptor antagonist (IL-1RA), or a bac-
terial b-galactosidase as a control [160, 212]. Following
these initial experiments several studies have been
published applying adenoviral vector constructs. These
studies include the use of in vivo injections of the
respective adenoviral construct in healthy or artificially
degenerated rabbit IVD [106, 142] as well as in vitro
transfections of human disc derived cells [136]. Taken
together, these studies have demonstrated that adeno-
viral vectors are able to efficiently transform disc cells
from various species. Importantly, no evidence has been
reported that the efficiency of the gene transfer might
depend on the degeneration state of the donor tissue, a
prerequisite for a broad application of this technique.
However, these studies do not sufficiently address
concerns about safety of these vectors in clinical appli-
cations. The main disadvantage of adenoviral vectors
lies in the activation of innate and adaptive parts of the
patient’s immune system when the vector is applied in
vivo. The resulting inflammatory responses induced by
these vectors can be very strong and even fatal [164,
186]. To overcome this drawback, Lattermann et al.
[109] recently tested an adeno-associated viral vector
(AAV) for its applicability to disc degeneration treat-
ment. The authors demonstrated that AAV was able to
efficiently transduce human disc cells in vitro and rabbit
disc cells in vivo. Although AAV caused a humoral
immune response, no significant cellular immune re-
sponse, as seen with adenoviral vectors, was observed.
Interestingly, despite the observed humoral immune
response, significant transgene expression was observed
in the pre-exposed animals [109]. These findings suggest
that AAV might offer a valuable and safer alternative
to adenoviral vectors in the future.
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Although the above studies suggest the feasibility of
direct gene therapy using viral vectors to target disc
cells, the question of the delivered gene and therefore
expressed gene product remains open. Among the
potentially beneficial genes tested so far are the ana-
bolic factors transforming growth factor-b1 (TGF-b1),
LMP-1 (LIM (LIM domain named after the three first
described homeodomain proteins Lin-11, Isl-1, and
Mec-3) mineralization protein-1)and Sox9 (SRY (sex-
determining region Y)-box 9), and the anti-catabolic
factor TIMP-1.
The first study to deliver an exogenous therapeutic
gene in vivo in was performed by Nishida et al. using
an adenoviral vector carrying the gene for TGF-b1 to
modify cells of rabbit IVD [142]. The authors found
significant increases of TGF-b1 and also proteoglycan
production in the injected disc, suggesting the feasi-
bility of direct gene therapy to treat intervertebral disc
diseases [142].
An alternative potentially beneficial factor, LMP-1,
has been shown to positively affect the degenerated disc
matrix by increasing the disc cell production of BMPs
and proteoglycans in vitro [219]. Intradiscal injection of
rabbit discs in vivo resulted in increased expression of
the anabolic cytokines BMP-2 and BMP-7 mRNA and
also led to increased production of aggrecan mRNA
[219]. These data suggest that LMP-1 is also a beneficial
factor that could be applied to gene therapeutically
treat disc degeneration. In contrast to the proteins
discussed so far, Sox9 does not influence the proteo-
glycan content in the disc matrix. As a transcription
factor responsible for the synthesis of type II collagen,
its transfer into cells from degenerated human discs
resulted in increased levels of type II collagen [153].
Injection of a Sox9 carrying adenoviral vector into
stabbed rabbit discs resulted in preservation of the
histologic appearance seen in healthy discs, whereas the
stabbed control discs displayed degeneration-typical
alterations [153]. Therefore, not only increased pro-
teoglycan production but also collagen type II produc-
tion seems to be able to prevent disc degeneration in
vivo and thereby offering an attractive alternative
therapeutic approach. Although the promising re-
sponses of disc cells to transformation with activating
factors, it is conceivable that the increased production
of a single growth factor or transcription factor might
results in sub-optimal responses. A combination of re-
lated or, better, synergetic factors might be more
physiological and therefore might lead to better results.
In a recent study the combined transfer of TGF-b1,
IGF-1 and BMP-2 revealed not only an additive effect
of these factors on protein synthesis but also a syner-
gistic amplification of protein synthesis [137].
Besides the use of anabolic factors to induce in-
creased production of matrix components by disc cells,
application of anti-catabolic factors might provide an
interesting alternative. Catabolic inhibition would al-
low maintaining or increasing the content of the
respective matrix component by slowing down its
degradation without the need to force the disc cells to
higher synthesis rates. Using an adenoviral vector, the
gene encoding for TIMP-1 was introduced in vitro into
disc cells isolated from degenerated human IVD. Gene
delivery of TIMP-1 increased the proteoglycan content
in the disc cell cultures, suggesting the anti-catabolic
approach to be a new and promising strategy for gene
therapy of degenerated discs [209].
Although these results sound very promising, the
application to human IVD will be complicated by the
adverse microenvironment inside a severely degener-
ated disc. Considering the compromised disc cell
physiology due to deprivation of nutrients like glucose
or oxygen and also the lowered pH due to accumula-
tion of lactic acid, it is questionable if these cells will be
able to produce reasonable amounts of growth factors
over a significant period of time. Even if the produc-
tion of the respective gene product could be achieved,
it can be doubted that the surrounding, starving cells
are able to properly respond and produce an improved
matrix. Despite originating from degenerated discs, the
cells used during in vitro studies have been brought to
and analyzed in a completely different environment
that barely resembles the in vivo situation. Therefore,
extrapolations from these in vitro experiments to the
abilities of transformed cells in vivo have to be very
cautious. In this context it will be interesting to see how
the anti-catabolic approach proves in the in vivo situ-
ation compared to the use of anabolic factors. The
unavailability of a suitable animal model that would
include the deprivation of nutrients from the disc cells
is further complicating predictions about the applica-
bility of direct gene therapy to degenerative disc dis-
eases in humans.
Supplementation with autologous cells
Alternatively to genetically modifying resident disc
cells, degenerated discs could be treated by supple-
mentation of the deserted matrix with in vitro culti-
vated cells. To avoid immunological complications,
these cells should preferentially originate from the
patients body (autologous cells). Therefore, cells that
are compatible with the disc tissue have to be har-
vested, expanded in vitro and subsequently implanted
into the affected tissue. Once the cells have been re-
moved and cultivated in vitro, this approach allows for
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genetic modifications of the withdrawn cells (= indirect
gene therapy) and/or seeding of the cells in supporting
biomaterials (= tissue engineering) prior to implanta-
tion into the degenerated disc (Fig. 5). The combina-
tion of these techniques potentially improves the
efficiency of the original approach by improving cell
survival or enhancing the biosynthetic activity of the
implanted cells. Since the genetic modification of cul-
tivated cells in vitro is technically very similar to the
approaches discussed above, we will focus here on the
cultivation of disc cells and generation of suitable im-
plants.
Compared to similar approaches in articular carti-
lage, it is substantially more difficult to obtain suitable
and sufficient numbers of target cells from interverte-
bral disc tissue. Removal of nucleus pulposus cells, the
obvious target cells, would require opening of the
anulus fibrosus to gain access. On the other side, re-
moval of anulus fibrosus cells would necessarily cause
damage to the anulus. In addition to the very restricted
accessibility, the very low cell density in degenerated
discs will further complicate the acquisition of ample
cells for successful in vitro cultivation. Therefore, only
a limited number of scenarios are conceivable that
would allow the withdrawal of sufficient cells from the
disc to perform a disc cell-based approach without
further damaging the already affected disc or acceler-
ating its degeneration. Withdrawal of herniated disc
material might be one scenario that would facilitate the
removal of sufficient disc cells for in vitro cultivation.
However, the introduction of cells/implants after a
surgical intervention on the same disc is disputed since
the outcome of minimally invasive nucleotomy has
been shown satisfactory for most patients [130]. An-
other conceivable scenario would be the use of cell-
based approaches to prevent the accelerated degener-
ation of discs adjacent to an interbody fusion level [32,
100, 114]. The disc material removed during the fusion
procedure could be used as source of cells to treat the
adjacent disc. However, this would imply an interven-
tion at a non-degenerated disc that only has the po-
tential to degenerate later on and is therefore rather
questionable. Taken together, with our current tech-
niques, autologous disc cell transplantation is limited to
few scenarios but has the potential to prove as a
powerful approach within these limitations.
The most straightforward approach to augment a
degenerated disc by autologous cells would be injecting
a suspension of ex vivo proliferated disc cells [54, 55].
This approach is also the only one applied in clinical
trials so far [55]. In these studies, the outcome was
mostly satisfying with the patients significantly
improving. However, the scientific data published on
this approach are rather sparse. Information about cell
survival, phenotype of the implanted cells and the
biosynthetic abilities of these cells is not available so
far. In addition, animal experiments have raised the
issue that injection of a cell suspension into rabbit
IVDs led to extensive leakage of the cells through the
injection site [18]. So far it is not clear, why this leakage
was not observed during the clinical studies or if the
leakage probably was delayed and not recognized. In
the animal model the leakage was significantly reduced
by suspending the cells in a fibrinogen–thrombin
solution (i.e. matrix-assisted cell transfer). However,
this study also suggested that preceding nucleotomy
and supplementation of the cells with nutrients is
necessary for injection and also matrix-assisted transfer
approaches in order to permit survival of the injected
cells [18]. Although data from animal experiments and
human clinical studies cannot be directly compared,
the observations from the animal experiments raise the
question if and how the cells injected into the herniated
human disc survive. Further investigation on the fate of
the implanted cells in vivo is therefore definitely nee-
ded.
An approach to prepare autologous disc cells for
subsequent transplantation into the degenerated disc is
the cultivation of the disc cells in three-dimensional
cultivation systems. This approach is based on early
observations during routine monolayer cultivation of
disc cells that led to dedifferentiation of the cells with
concurrent morphological changes [14, 107, 127].
Maldonado et al. then demonstrated that cultivation of
disc cells in three-dimensional constructs conserved the
native phenotype, as shown by the synthesis of matrix
components similar to those observed in native discs
[127]. Since the initial experiments a wide variety of
techniques has been recently applied to supply disc
cells with the desired three-dimensional arrangements
(reviewed in [63]). Herein, we will describe experi-
mental strategies whose feasibility has been tested in
vivo, i.e. in animal experiments, and discuss these ap-
proaches.
In a study using a Sand Rat-based model system,
Gruber et al. applied autologous disc cells, expanded in
routine monolayer cultures and seeded into a three-
dimensional scaffold, to a hollowed cavity created in
the acceptor intervertebral disc [64]. After up to
33 weeks, no giant cell response was observed and the
cells showed an appropriate morphology. In addition,
no abnormality in the cell-surrounding matrix was
observed, suggesting appropriate survival of the im-
planted cells during the analyzed time period. From
their data the authors conclude that autologous disc
cell implantation can be successful, although techni-
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cally challenging. However, due to the immediate
implantation after the seeding of the scaffold, the disc
cells do not have the time to synthesize appropriate
amounts of matrix before encountering the microen-
vironmental conditions inside the disc. Although this
technique was successful in the given animal model,
the cells might not have survived implantation into the
hostile environment inside a degenerated human disc.
Cultivation of the disc cells in a three-dimensional
system prior to implantation might therefore improve
the chances for survival in the hostile environment.
This improved approach was tested by Sato et al. [175–
177] using a scaffold based on the non-immunogenic
collagen derivative atelocollagen that has previously
been tested in vitro and has been already applied to a
rabbit model system. Rabbit anulus fibrosus cells see-
ded and cultivated for up to 3 weeks in this scaffold
showed an increased ability to express type II collagen
mRNA and deposited more type II collagen and pro-
teoglycan compared to cells grown in monolayers. A-
telocollagen scaffolds seeded with anulus fibrosus cells
have been allografted into the lacunae of recipient
rabbits after laser discectomy of the nucleus pulposus
[175]. Implantation resulted in a significant prevention
of the narrowing of the intervertebral disc space up to
12 weeks postoperative compared to the nucleotom-
ized control animals. Histological analysis also showed
that the allografted cells were viable, proliferated and
produced a hyaline-like matrix in the disc tissue of the
recipients. Although the rabbit model does not
appropriately simulate the mechanical forces experi-
enced by implanted disc cell in human discs, it is con-
ceivable that cells surrounded by their own matrix
might withstand mechanical forces with more success.
However, experimental data are lacking to prove this
point. In addition, the application of the seeded scaf-
fold required a 16-gauge needle (approx. 1.65 mm
outside diameter) that would significantly damaged the
anulus fibrosus during implantation. It would therefore
be necessary to somehow close the gap in the anulus
fibrosus to avoid loss of the implanted construct upon
axial load.
Taken together the presented approaches suggest
that disc repair attempts with autologous disc cells
require a delicate balance between support of the
implanted cells and the feasibility of implantation
without detrimental damage of discal structures. An-
other problem not addressed by the presented studies
is the acute shortage of nutrients experienced by the
cells after implantation into the degenerated disc.
Considering that the nutrient supply is hardly suffi-
cient for the original disc cells, it is questionable if the
additional cells will survive for a prolonged time span
in order to provide a sustained improvement of the
disc.
Stem cell-based gene therapies
A recent development in tissue engineering techniques
might bear the potential to circumvent at least some
problems encountered with the standard tissue engi-
neering/gene therapy approaches (Fig. 6).
Adult mesenchymal stem cells are uncommitted
pluripotent stem cells that are found in several tissues
like skeletal muscle, bone marrow, synovial mem-
branes and dermis [19, 20, 39, 81, 154, 220]. Mesen-
chymal stem cells are of high plasticity and have a high
capacity of multilineage differentiation. In addition,
they are accessible and comparably easy to manipulate,
making them natural candidates for orthopedic gene
therapy studies [53]. In order to engineer the isolated
stem cells several vector system have already been
tested on adult mesenchymal stem cells and high
transduction and expression rates have been achieved
[89, 108, 119]. However, transforming of isolated
mesenchymal stem cells is only one step on the way to
its use for cell-based therapy. Being undifferentiated
the stem cells’ differentiation has to be directed to
yield chondrocytes or chondrocyte-like cells. Members
of the BMP family of growth factors have been used so
far to induce differentiation of mesenchymal stem cells
into chondrocytes [1, 105, 132]. However, since BMP
are not exclusively inducing cartilage differentiation,
its expression needs to be carefully timed and modu-
lated to avoid the sequent generation of bone struc-
tures. To overcome this problem, signal transduction
factors that exclusively induced cartilage differentia-
tion, have been tested. Members of the Sox family of
transcription factors and a novel transcription factor,
Brachyury, are potential candidates and have been
tested with encouraging results [5, 50, 74]. Recently, it
has been found that already co-cultivation of MSCs
with disc cells might be sufficient to induce a disc cell-
like phenotype in MSCs [99, 113, 162, 182]. Although
these data origin from in vitro experiments, it might be
conceivable that MSCs would also differentiate when
brought into contact with disc cells in vivo, i.e. after
injection into the disc. Besides the co-cultivation with
disc cells, cultivating of mesenchymal stem cells in
three-dimensional cultivating systems appears to be
sufficient to induce a nucleus pulposus-like phenotype
[163]. Implantation of collagen-gel-embedded mesen-
chymal stem cells into artificially degenerated rabbit
discs resulted in preserved nuclear and anular struc-
tures, prevention of proteoglycan decrease from the
nucleus pulposus and increased disc height [170–172].
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The implanted cells were shown to survive and express
genetic markers typical for nucleus pulposus cells.
Similar results were also found after injection of a
bone-derived MSC suspension into rabbit discs and
injection of gel embedded MSCs into rat coccygeal
discs [35, 223].
The use of mesenchymal stem cells provides a new
and exciting approach to biologically treat disc
degeneration with so far encouraging results. The
comparably easy access to autologous mesenchymal
stem cells allows overcoming one of the major culprits
of conventional approaches. However, there are many
open questions before the real potential of this tech-
nique can be judged. Since the exact phenotype of
nucleus pulposus cells and their origin are still not
undoubtedly defined it is nearly impossible to find a
definitive answer if the phenotype of the differentiated
MSCs is identical or only similar to the original nucleus
pulposus cells. Although recent data indicate a very
good accordance between differentiated MSCs and
native disc cells [190], it is not yet clear if the newly
adopted phenotype is stable over a prolonged time and
during the severely changing environmental conditions
as disc degeneration progresses. Another unclarity that
also affects autologous cell transplantation approaches
is the quality of the newly synthesized matrix regarding
biomechanical properties. Is the new disc matrix, de-
spite its biochemical similarity to the original matrix,
able to bear the mechanical load experienced during
the daily life of the individual? These questions are of
outmost importance and might put the stem cell ap-
proach into perspective. However, the high expand-
ability of MSCs together with the relative easiness to
harvest the cells makes this approach highly attractive.
In addition, recent studies have shown that MSCs lack
MHC class I receptors [110] and that human recipients
receiving MHCs from sibling donors do not exhibit an
immunogenic response [77] suggesting that allogenic
MSCs could be used, which would further encourage
the use of MSC for disc repair approaches. However,
more and extended studies are required to analyze the
long-term properties of the newly formed tissue and to
prove its value under mechanical load in the spine of
bipedal vertebrate.
Future directions
The intervertebral disc has been shown to be a very
unique, highly specialized tissue that undergoes mas-
sive alterations during degeneration. The functions of
the disc require a mechanically stable structure with a
highly specialized matrix to confer the needed flexi-
bility and physical strength to the spine. Especially
the bipedal gait of human beings causes severe
mechanical stress to the intervertebral disc. To with-
stand these forces the intervertebral disc is necessarily
‘designed’ as a self-contained structure. However,
self-containment has not only beneficial effects for the
disc. The observed avascularity of the adult disc re-
stricts nutrient supply to diffusion and therefore poses
a major challenge for the prolonged maintenance of
the discal matrix by the disc cells. Mechanical stress
and nutrient restriction finally create a hostile envi-
ronment, resulting in progressing death of the matrix
maintaining cells and, concomitant, to an extensive
decay of the matrix.
These properties and its alterations during degen-
eration limit and define the techniques applicable to
biologically repair degenerated IVD. Although the
self-contained and avascular structure would favor di-
rect gene therapy, the very limited numbers of cells
and the compact matrix in the degenerated disc out-
weigh the immunological advantages. Improved carrier
systems to efficiently deliver genetic material to the
disc cells might overcome this major disadvantage, but
until then direct gene therapy might be an inferior
strategy.
By autologous implantation of in vitro cultivated
disc cells, disc cell implantation has the potential to
refresh the number of viable cells, and therefore the
matrix, inside the degenerated disc. However, the
degenerative decay of the discal matrix leaves an ex-
hausted desert that will inescapable become the host of
the in vitro generated tissue, and therefore putting
huge demands on the implanted cells. Despite the
numerous studies that have broadened our under-
standing of the biochemistry and the capability of disc
cells, it is questionable if the cells can be prepared in
vitro for prolonged survival and proper functioning
under such adverse conditions.
Because of the band-width of degenerative altera-
tions, different stages of degeneration will require
different approaches. Putative biological therapies will
need to be tailored for the treatment of a defined grade
of degeneration. Therefore, criteria will need to be
defined to decide if and with which technique a certain
degenerated disc might be treated.
Taken together, these concerns might indicate that
the clinical application of gene therapy/tissue engi-
neering techniques to regenerate degenerated IVD is
still far away. With our current technology, gene
therapy of the degenerate disc might be compared to
attempts to jumpstart a car that ran out of fuel. How-
ever, based on the recent insights into signal trans-
duction mechanisms that might lead to the induction of
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pain by degenerated discs, it is conceivable that ther-
apies targeting pro-inflammatory signaling pathways
might be successful in the foreseeable future. Such
therapies might not have the ability to reverse the
progressing tissue destruction which occurs with ageing
but may transform a symptomatic to an asymptomatic
disc degeneration and thereby greatly improve life
quality of the affected patients.
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